Nilutamide Disease Interactions

The use of nilutamide is contraindicated in patients with severe hepatic impairment. Patients with hepatic dysfunction may be at increased risk for nilutamide- associated hepatitis and marked increases in liver enzymes. Nilutamide is extensively metabolized by the liver and the metabolic activity and disposition of nilutamide may be altered in patients with severe hepatic impairment. Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Clinical monitoring of hepatic function is recommended and nilutamide should be discontinued if liver transaminase levels increase two to three times the upper limit of normal.

The use of nilutamide is contraindicated in patients with severe respiratory impairment. Patients with pulmonary dysfunction may be at increased risk for nilutamide- associated interstitial pneumonitis. Patients should be instructed to immediately report any signs or symptoms of respiratory impairment such as dyspnea, cough, chest pain, or fever. Clinical monitoring of pulmonary function, including pre-treatment chest X-ray, is recommended.